NRSG 2350 Pathophysiology & Pharmacology Exam 1 Prep
Document | 2026/2027 Edition | 250 Verified Questions
NRSG 2350 Pathophysiology & Pharmacology Exam 1 2026-2027 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NRSG 2350 Pathophysiology & Pharmacology
Exam 1 contains 250 verified questions with detailed rationales. It is meticulously aligned with the
2026/2027 academic year curriculum and the latest clinical guidelines. Each question is designed to
test critical thinking and application of core concepts in pathophysiology and pharmacology. The
document serves as an essential resource for nursing students aiming to excel in their midterm
examination.
Key Features:
Cellular adaptation and injury mechanisms
Fluid, electrolyte, and acid-base imbalances
Pharmacokinetics and pharmacodynamics principles
Autonomic nervous system pharmacology
Inflammation and immune response pharmacology
Updates for 2026:
- Revised rationales to reflect the latest evidence-based practice guidelines
- Incorporated new questions on emerging pharmacological therapies
- Updated drug classifications and nursing considerations per 2026-2027 standards
- Enhanced explanations for pathophysiological processes with current research
- Aligned content with the latest NCLEX-RN test plan and HESI exam blueprints
Abstract:
This exam preparation guide for NRSG 2350 Pathophysiology & Pharmacology Exam 1 provides a rigorous
review of essential concepts required for nursing practice. The document integrates foundational knowledge of
disease processes with pharmacological interventions, emphasizing the interplay between pathophysiology and
drug therapy. Each of the 250 questions is accompanied by a thorough rationale that explains the correct answer
and distracts, fostering deeper understanding. The content is organized to mirror the exam blueprint, ensuring
comprehensive coverage of topics such as cellular biology, inflammation, fluid balance, and drug classifications.
Updated for the 2026/2027 academic year, this resource is indispensable for students seeking to achieve a high
score and demonstrate clinical competence. The rationales are crafted to enhance critical thinking and
application, preparing students for both the exam and real-world clinical scenarios. This document is a testament
to academic excellence and a must-have for any nursing student enrolled in NRSG 2350.
Keywords:
Pathophysiology, Pharmacology, NRSG 2350, Exam 1, Nursing, Rationales, Verified Answers, 2026-2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining the underlying pathophysiological or pharmacological principle.
Distractor rationales are also provided to clarify common misconceptions and reinforce learning.
Compliance Checklist:
Aligned with 2026-2027 NRSG 2350 course objectives
Updated to reflect the latest clinical practice guidelines
Includes rationales for both correct and incorrect answers
Page 1
, Covers all major content areas as per the exam blueprint
Suitable for NCLEX-RN and HESI exam preparation
Verified by subject matter experts for accuracy
Content Area Overview:
Content Area Questions Key Topics Weight
Cellular Biology & Adaptation 1-50 Cell injury, adaptation, necrosis, apoptosis, 20%
neoplasia
Fluid, Electrolyte, & Acid-Base 51-90 Fluid shifts, electrolyte imbalances, 16%
Balance acid-base disorders
Pharmacokinetics & 91-130 ADME, receptor theory, dose-response, drug 16%
Pharmacodynamics interactions
Autonomic Nervous System 131-170 Cholinergic, adrenergic agonists/antagonists 16%
Pharmacology
Inflammation & Immune 171-210 Inflammatory mediators, 16%
Response immunosuppressants, anti-inflammatory
drugs
Cardiovascular & Renal 211-250 Antihypertensives, diuretics, cardiac 16%
Pharmacology glycosides, antiarrhythmics
Page 2
,Q1. A patient with chronic heart failure and reduced ejection fraction is initiated on
sacubitril/valsartan. Which mechanism best explains the combined benefit and
primary risk of this therapy?
A. Inhibition of neprilysin increases natriuretic peptides but also raises angiotensin II
levels, countered by valsartan.
B. Blockade of angiotensin II receptors alone reduces preload and afterload without
affecting bradykinin metabolism.
C. Enhancement of bradykinin degradation potentiates vasodilation but increases the
risk of angioedema.
D. Combined ACE inhibition and angiotensin receptor blockade maximizes
neurohormonal suppression but causes hyperkalemia.
Correct Answer: A. Inhibition of neprilysin increases natriuretic peptides but also
raises angiotensin II levels, countered by valsartan.
Rationale: Sacubitril inhibits neprilysin, increasing natriuretic peptides (beneficial) and
also increasing angiotensin II (harmful), which is blocked by valsartan. This dual
mechanism improves outcomes but carries risks of hypotension, hyperkalemia, and
angioedema (though less than ACE inhibitors). Option A correctly identifies the
mechanism and counterbalance.
Why Wrong:
B - Incorrect: Valsartan alone does not address the neprilysin pathway; the benefit
comes from combined neprilysin inhibition and AT1 blockade.
C - Incorrect: Sacubitril inhibits neprilysin, which degrades bradykinin, thus
bradykinin levels increase, not decrease; increased bradykinin contributes to
angioedema risk.
D - Incorrect: Sacubitril/valsartan is not an ACE inhibitor; it combines an ARB with a
neprilysin inhibitor, not ACE inhibition plus ARB.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 27.
Q2. A researcher is investigating a novel drug that selectively inhibits the late sodium
current in cardiac myocytes. Which arrhythmia mechanism is most directly targeted,
and what is the expected clinical effect?
A. Suppression of early afterdepolarizations in long QT syndrome, reducing torsades
de pointes risk.
B. Blockade of the rapid delayed rectifier potassium current, prolonging repolarization
and preventing reentry.
C. Inhibition of calcium overload in ischemia, preventing delayed afterdepolarizations
and triggered activity.
D. Enhancement of sodium-calcium exchange, accelerating phase 4 depolarization and
automaticity.
Page 3
, Correct Answer: A. Suppression of early afterdepolarizations in long QT syndrome,
reducing torsades de pointes risk.
Rationale: The late sodium current (INa-L) is enhanced in conditions like long QT
syndrome and ischemia, causing sodium overload and early afterdepolarizations (EADs)
that trigger torsades de pointes. Selective inhibition of INa-L suppresses EADs, thus
reducing the risk of polymorphic ventricular tachycardia. Options B, C, and D describe
different ion channel effects.
Why Wrong:
B - Incorrect: Blocking IKr would prolong repolarization and worsen long QT, not
target the late sodium current.
C - Incorrect: Inhibition of calcium overload is a mechanism of ranolazine, but the
primary targeted current is late sodium, not calcium directly.
D - Incorrect: Enhancing sodium-calcium exchange would increase automaticity and
promote arrhythmias, opposite of therapeutic intent.
Reference: Katzung, B.G. (2025). Basic & Clinical Pharmacology, 16th Ed., Ch. 14.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min) is
prescribed dapagliflozin. Which statement best explains the cardiovascular benefit
and a key safety consideration?
A. SGLT2 inhibition reduces preload and afterload via osmotic diuresis, but may cause
euglycemic ketoacidosis even with near-normal glucose.
B. SGLT2 inhibition improves cardiac efficiency by increasing ketone utilization, but
requires dose adjustment for renal function.
C. SGLT2 inhibition lowers blood pressure by natriuresis, but is contraindicated if
eGFR is below 45 mL/min.
D. SGLT2 inhibition promotes weight loss via glycosuria, but increases the risk of
urinary tract infections due to glucosuria.
Correct Answer: A. SGLT2 inhibition reduces preload and afterload via osmotic
diuresis, but may cause euglycemic ketoacidosis even with near-normal glucose.
Rationale: SGLT2 inhibitors like dapagliflozin reduce cardiovascular events through
hemodynamic effects (reduced preload/afterload) and metabolic shifts. A major safety
concern is euglycemic diabetic ketoacidosis (euDKA), which can occur with blood glucose
levels near normal, especially in patients with reduced insulin reserve. Dapagliflozin can
be used down to eGFR 30 mL/min, but efficacy is reduced; it is not contraindicated at 35.
Option A correctly pairs benefit and risk.
Why Wrong:
B - Incorrect: While ketone utilization is proposed, the primary cardiovascular
mechanism is hemodynamic; dapagliflozin does not require dose adjustment for renal
function but is less effective at low eGFR.
C - Incorrect: Dapagliflozin is not contraindicated at eGFR 35; it can be used down to
Page 4
Document | 2026/2027 Edition | 250 Verified Questions
NRSG 2350 Pathophysiology & Pharmacology Exam 1 2026-2027 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document for NRSG 2350 Pathophysiology & Pharmacology
Exam 1 contains 250 verified questions with detailed rationales. It is meticulously aligned with the
2026/2027 academic year curriculum and the latest clinical guidelines. Each question is designed to
test critical thinking and application of core concepts in pathophysiology and pharmacology. The
document serves as an essential resource for nursing students aiming to excel in their midterm
examination.
Key Features:
Cellular adaptation and injury mechanisms
Fluid, electrolyte, and acid-base imbalances
Pharmacokinetics and pharmacodynamics principles
Autonomic nervous system pharmacology
Inflammation and immune response pharmacology
Updates for 2026:
- Revised rationales to reflect the latest evidence-based practice guidelines
- Incorporated new questions on emerging pharmacological therapies
- Updated drug classifications and nursing considerations per 2026-2027 standards
- Enhanced explanations for pathophysiological processes with current research
- Aligned content with the latest NCLEX-RN test plan and HESI exam blueprints
Abstract:
This exam preparation guide for NRSG 2350 Pathophysiology & Pharmacology Exam 1 provides a rigorous
review of essential concepts required for nursing practice. The document integrates foundational knowledge of
disease processes with pharmacological interventions, emphasizing the interplay between pathophysiology and
drug therapy. Each of the 250 questions is accompanied by a thorough rationale that explains the correct answer
and distracts, fostering deeper understanding. The content is organized to mirror the exam blueprint, ensuring
comprehensive coverage of topics such as cellular biology, inflammation, fluid balance, and drug classifications.
Updated for the 2026/2027 academic year, this resource is indispensable for students seeking to achieve a high
score and demonstrate clinical competence. The rationales are crafted to enhance critical thinking and
application, preparing students for both the exam and real-world clinical scenarios. This document is a testament
to academic excellence and a must-have for any nursing student enrolled in NRSG 2350.
Keywords:
Pathophysiology, Pharmacology, NRSG 2350, Exam 1, Nursing, Rationales, Verified Answers, 2026-2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining the underlying pathophysiological or pharmacological principle.
Distractor rationales are also provided to clarify common misconceptions and reinforce learning.
Compliance Checklist:
Aligned with 2026-2027 NRSG 2350 course objectives
Updated to reflect the latest clinical practice guidelines
Includes rationales for both correct and incorrect answers
Page 1
, Covers all major content areas as per the exam blueprint
Suitable for NCLEX-RN and HESI exam preparation
Verified by subject matter experts for accuracy
Content Area Overview:
Content Area Questions Key Topics Weight
Cellular Biology & Adaptation 1-50 Cell injury, adaptation, necrosis, apoptosis, 20%
neoplasia
Fluid, Electrolyte, & Acid-Base 51-90 Fluid shifts, electrolyte imbalances, 16%
Balance acid-base disorders
Pharmacokinetics & 91-130 ADME, receptor theory, dose-response, drug 16%
Pharmacodynamics interactions
Autonomic Nervous System 131-170 Cholinergic, adrenergic agonists/antagonists 16%
Pharmacology
Inflammation & Immune 171-210 Inflammatory mediators, 16%
Response immunosuppressants, anti-inflammatory
drugs
Cardiovascular & Renal 211-250 Antihypertensives, diuretics, cardiac 16%
Pharmacology glycosides, antiarrhythmics
Page 2
,Q1. A patient with chronic heart failure and reduced ejection fraction is initiated on
sacubitril/valsartan. Which mechanism best explains the combined benefit and
primary risk of this therapy?
A. Inhibition of neprilysin increases natriuretic peptides but also raises angiotensin II
levels, countered by valsartan.
B. Blockade of angiotensin II receptors alone reduces preload and afterload without
affecting bradykinin metabolism.
C. Enhancement of bradykinin degradation potentiates vasodilation but increases the
risk of angioedema.
D. Combined ACE inhibition and angiotensin receptor blockade maximizes
neurohormonal suppression but causes hyperkalemia.
Correct Answer: A. Inhibition of neprilysin increases natriuretic peptides but also
raises angiotensin II levels, countered by valsartan.
Rationale: Sacubitril inhibits neprilysin, increasing natriuretic peptides (beneficial) and
also increasing angiotensin II (harmful), which is blocked by valsartan. This dual
mechanism improves outcomes but carries risks of hypotension, hyperkalemia, and
angioedema (though less than ACE inhibitors). Option A correctly identifies the
mechanism and counterbalance.
Why Wrong:
B - Incorrect: Valsartan alone does not address the neprilysin pathway; the benefit
comes from combined neprilysin inhibition and AT1 blockade.
C - Incorrect: Sacubitril inhibits neprilysin, which degrades bradykinin, thus
bradykinin levels increase, not decrease; increased bradykinin contributes to
angioedema risk.
D - Incorrect: Sacubitril/valsartan is not an ACE inhibitor; it combines an ARB with a
neprilysin inhibitor, not ACE inhibition plus ARB.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 27.
Q2. A researcher is investigating a novel drug that selectively inhibits the late sodium
current in cardiac myocytes. Which arrhythmia mechanism is most directly targeted,
and what is the expected clinical effect?
A. Suppression of early afterdepolarizations in long QT syndrome, reducing torsades
de pointes risk.
B. Blockade of the rapid delayed rectifier potassium current, prolonging repolarization
and preventing reentry.
C. Inhibition of calcium overload in ischemia, preventing delayed afterdepolarizations
and triggered activity.
D. Enhancement of sodium-calcium exchange, accelerating phase 4 depolarization and
automaticity.
Page 3
, Correct Answer: A. Suppression of early afterdepolarizations in long QT syndrome,
reducing torsades de pointes risk.
Rationale: The late sodium current (INa-L) is enhanced in conditions like long QT
syndrome and ischemia, causing sodium overload and early afterdepolarizations (EADs)
that trigger torsades de pointes. Selective inhibition of INa-L suppresses EADs, thus
reducing the risk of polymorphic ventricular tachycardia. Options B, C, and D describe
different ion channel effects.
Why Wrong:
B - Incorrect: Blocking IKr would prolong repolarization and worsen long QT, not
target the late sodium current.
C - Incorrect: Inhibition of calcium overload is a mechanism of ranolazine, but the
primary targeted current is late sodium, not calcium directly.
D - Incorrect: Enhancing sodium-calcium exchange would increase automaticity and
promote arrhythmias, opposite of therapeutic intent.
Reference: Katzung, B.G. (2025). Basic & Clinical Pharmacology, 16th Ed., Ch. 14.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min) is
prescribed dapagliflozin. Which statement best explains the cardiovascular benefit
and a key safety consideration?
A. SGLT2 inhibition reduces preload and afterload via osmotic diuresis, but may cause
euglycemic ketoacidosis even with near-normal glucose.
B. SGLT2 inhibition improves cardiac efficiency by increasing ketone utilization, but
requires dose adjustment for renal function.
C. SGLT2 inhibition lowers blood pressure by natriuresis, but is contraindicated if
eGFR is below 45 mL/min.
D. SGLT2 inhibition promotes weight loss via glycosuria, but increases the risk of
urinary tract infections due to glucosuria.
Correct Answer: A. SGLT2 inhibition reduces preload and afterload via osmotic
diuresis, but may cause euglycemic ketoacidosis even with near-normal glucose.
Rationale: SGLT2 inhibitors like dapagliflozin reduce cardiovascular events through
hemodynamic effects (reduced preload/afterload) and metabolic shifts. A major safety
concern is euglycemic diabetic ketoacidosis (euDKA), which can occur with blood glucose
levels near normal, especially in patients with reduced insulin reserve. Dapagliflozin can
be used down to eGFR 30 mL/min, but efficacy is reduced; it is not contraindicated at 35.
Option A correctly pairs benefit and risk.
Why Wrong:
B - Incorrect: While ketone utilization is proposed, the primary cardiovascular
mechanism is hemodynamic; dapagliflozin does not require dose adjustment for renal
function but is less effective at low eGFR.
C - Incorrect: Dapagliflozin is not contraindicated at eGFR 35; it can be used down to
Page 4
